Voya Investment Management LLC Sells 29,901 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Voya Investment Management LLC lowered its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 68.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,948 shares of the company's stock after selling 29,901 shares during the period. Voya Investment Management LLC's holdings in Pacira BioSciences were worth $263,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. ExodusPoint Capital Management LP raised its holdings in Pacira BioSciences by 232.6% in the 4th quarter. ExodusPoint Capital Management LP now owns 212,824 shares of the company's stock worth $4,010,000 after purchasing an additional 148,842 shares in the last quarter. Norges Bank bought a new position in Pacira BioSciences in the 4th quarter worth $2,405,000. Natixis bought a new position in Pacira BioSciences in the 4th quarter worth $1,738,000. Charles Schwab Investment Management Inc. raised its holdings in Pacira BioSciences by 16.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company's stock worth $9,462,000 after purchasing an additional 70,307 shares in the last quarter. Finally, Impax Asset Management Group plc raised its holdings in Pacira BioSciences by 14.8% in the 4th quarter. Impax Asset Management Group plc now owns 540,027 shares of the company's stock worth $10,174,000 after purchasing an additional 69,424 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Needham & Company LLC decreased their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. HC Wainwright increased their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Barclays increased their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and increased their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Pacira BioSciences presently has a consensus rating of "Hold" and a consensus target price of $26.44.

Pacira BioSciences Stock Up 1.0%

PCRX stock traded up $0.26 during trading on Friday, hitting $25.86. 1,145,487 shares of the stock traded hands, compared to its average volume of 971,239. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $31.64. The firm's 50 day moving average is $24.88 and its two-hundred day moving average is $22.44. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -12.74 and a beta of 0.56. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.